The Anatomy of a Biotech Collapse: What Killed 54gene?

The Anatomy of a Biotech Collapse: What Killed 54gene?

For 54gene — the Nigerian genomics startup that raised forty-five million dollars before winding down in 2023 — the popular story has two versions. Version one: a frontier-market bet that got ahead of itself, with a founder who misread the room. Version two: a visionary scientist pushed out by predatory investors who stripped the company for parts. Both versions are incomplete. And on Per Visum, incomplete is not good enough.

Frontier Afrika Ep.1 Mispriced & Moving: Africa Is Not Waiting

Join us as we amplify the voice of emerging African markets through conversations on investments and policies — on Africa's own terms, with the people at the forefront.